Area of research
Molecular Biology · History and Philosophy of Science
Research interest
Research interests include Protein Degradation and Inhibitors, Ubiquitin and proteasome pathways, Academic Writing and Publishing, and Cancer-related Molecular Pathways.
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader.
Figure S4 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Figure S3 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Figure S2 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Supplementary Data Legends from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Figure S5 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Data from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Figure S1 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity.
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader.
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy.
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer
Discovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers.
Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders.
MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration.
Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders.
Discovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2- Breast Cancer.
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer.
Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model.
Discovery of a Novel Series of <i>iso</i>-Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue Degraders.
Correction to "Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer".
Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX models
Ph+B-ALL is defined by BCR::ABL1-induced enhancer reprogramming and hypersensitivity to enhancer-targeting drugs
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.